Topical Antiperspirant for Hand-Foot Syndrome
Phase 2
Completed
- Conditions
- Palmar-plantar Erythrodysesthesia
- Interventions
- Drug: antiperspirant
- Registration Number
- NCT00213993
- Lead Sponsor
- University of Wisconsin, Madison
- Brief Summary
The objectives of this study are to evaluate the effectiveness of an antiperspirant in preventing or attenuating the severity of palmer-plantar erythrodysesthesia associated with the Food and Drug Administration (FDA)-approved doses of capecitabine. The hypothesis is that cytotoxic compounds in sweat will be prevented from being deposited in the skin and causing chronic toxicity.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
- Has not previously received a regimen that includes 5-fluorouracil
- > 18 years old
- No known allergy or intolerance to Ban Unscented Roll-On Antiperspirant
Exclusion Criteria
- < 18 years of age
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description A antiperspirant antiperspirant topically to one foot once daily
- Primary Outcome Measures
Name Time Method reduction in palm and/or sole pain after each of first four cycles of chemotherapy
- Secondary Outcome Measures
Name Time Method evaluation of utility of digital photography in the following palmar-plantar erythrodysesthesia (PPES) after each of first four cycles of chemotherapy
Trial Locations
- Locations (1)
University of Wisconsin
🇺🇸Madison, Wisconsin, United States